GLACIER and ICICLE update; survival outcomes
Research type
Research Study
Full title
A follow-up of GLACIER (a study to investigate the Genetics of LobulAr Carcinoma In situ in EuRope) and ICICLE (A study to Investigate the genetiCs of In situ Carcinoma of the ductaL subtypE).
IRAS ID
230999
Contact name
Elinor Sawyer
Contact email
Sponsor organisation
Kings College London
Duration of Study in the UK
5 years, 0 months, 31 days
Research summary
A follow-up to the GLACIER and ICICLE studies, 5-10 years after initial recruitment of participants, in order to investigate survival of breast carcinoma, rates of recurrence and new diagnoses in women with differing subtypes of disease.\nThis aim of the study is to obtain follow-up data on participants with lobular carcinoma in situ, invasive lobular carcinoma and ductal carcinoma in situ who were recruited to the GLACIER and ICICLE studies between 2007 and 2013. Original GLACIER and ICICLE data was collected and is stored at QMUL, with each participant pseudonymised and assigned a unique trial number. Professor Elinor Sawyer holds an honorary contract with QMUL and therefore holds responsibility for identifying those patients who consented to further follow-up as part of the original GLACIER and ICICLE studies. Participants who consented for their information to be used in further studies will be deanonymised by the research team and identifiable information on NHS number, name and postcode gained. An application will be made to Public Health England for the return of up-to-date data relating to date and cause of death, recurrence of disease and any new diagnosis of breast carcinoma, for all participants who signed consent and agreed to future study in the original strands of GLACIER and ICICLE. This data will be linked to lifestyle information and family history data collected at baseline and genetic data generated as part of the studies from blood samples and tissue blocks collected at entry into the studies . These genetic markers will be assessed for an association with breast cancer survival. Any biomarkers identified will be utilised clinically to identify which women with early or in situ breast cancer require more intensive treatment, and will allow tailoring of specific treatment regimens for women with breast cancer in order to improve survival.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
18/SW/0052
Date of REC Opinion
16 Feb 2018
REC opinion
Favourable Opinion